Epidemiological Monitoring and Quality Control of Nuchal Translucency Jack Canick Intensive Course on Screening for Down’s Syndrome Wolfson Institute of.

Slides:



Advertisements
Similar presentations
Examples of Sound Screening:
Advertisements

SOUTH AUSTRALIAN MATERNAL SERUM ANTENATAL SCREENING (SAMSAS© ) PROGRAM
TEMPLATE DESIGN © Comparison of outcomes of triplet pregnancy with twin pregnancy Kyu-Sang Kyeong, M.D., Jae-Yoon Shim,
SOCIAL IMPLICATIONS OF GENETIC PRENATAL SCREENING IN PREGNANCY.
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Prenatal Screening Using Free DNA in Maternal Blood Jacob Canick, PhD Alpert Medical School of Brown University Women & Infants Hospital Providence, RI,
Towards Early Biochemical Screening for Fetal Aneuploidy in the First Trimester Niels Tørring 1, Olav B Petersen 2 1. Department of Clinical Biochemistry,
About these slides Provided by the CAP as an aid to pathologists to facilitate discussion on the topic. Content has been reviewed by experts at the CAP,
BROWN Prenatal Screening for Trisomy 21: Recent Advances and Guidelines Jacob Canick, PhD Alpert Medical School of Brown University Women & Infants Hospital.
Genetics and Primary Care
Prenatal Testing for Down Syndrome: Where Do We Stand Today? David B. Fox, MD Riverside Methodist Hospital.
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
Barbora Kubešová. Principles of screening  Simple, feasible  High sensitivity –detects disease, specifity – negative in unaffected individual  Ekonomically.
Antenatal Care DR. Yasir Katib MBBS, FRCSC Perinatologest.
Screening for fetal Down’s Syndrome – Improving efficacy and efficiency.
Enhanced Prenatal Screening Program
Jacob Canick, PhD on behalf of the FASTER Consortium 12 th International Conference on Prenatal Diagnosis and Therapy Budapest June 24-27, 2004 First and.
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
By : Drs Barati Drs Mohammadjafari Drs Masihi Drs aadati Drs Shahbazian DRS Zamanpoor(resident)
Milestones in Antenatal Screening Intensive Course on Screening for Down’s Syndrome Wolfson Institute of Preventive Medicine London May 2013 Jack Canick.
Pregnancy & Newborn Screening Developments
Photo: courtesy Travel Alberta.  The provision of information for individuals  Women have the right to access information about the health of their.
Women’s health in pregnancy and post- partum Michelle Wise BSc MD FRCSC MSc Senior Lecturer, Department of Obstetrics & Gynaecology, U of A Consultant.
How good is ultrasound prediction of fetal birth weight at term? Enya Ho Ranen Reddy.
First Trimester Screening
The State of Ohio Universal Prenatal Booking David S. McKenna, MD, RDMS Maternal-Fetal Medicine Miami Valley Hospital, Dayton OH.
Objectives Goals of the week scanGoals of the week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in.
Report of Iranian fetuses’s CRL at GA between 11W+0D to 13W+6D
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
In the name of god First Trimester Screening Dr.M.Moradi.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
ACB Training Course- Plymouth Down’s syndrome screening David Worthington (Laboratory Advisor - National Screening Programme)
Antenatal Care DR. Yasir Katib MBBS, FRCSC Perinatologist.
Obstetric Ultrasound + Fetal Medicine Annual report.
The Role of Prenatal screening as part of Routine Obstetric Care
NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010.
Conceptual & technical advances in Down’s syndrome screening Howard Cuckle
Screening for Down’s syndrome
Definition & Risk Factors of FGR FGR, also called IUGR is the term used to describe a fetus that has not reached its growth potential because of genetic.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
UOG Journal Club: January 2016 Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results.
Genetic Counseling and Prenatal Diagnosis Dr. Hassan Nasrat FRCS & FRCOG Professor Dept. Obstetrics & Gynecology King Abdulaziz University Hospital.
UOG Journal Club: March 2016 Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of.
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
UOG Journal Club: January 2016
بنام خدا.
UOG Journal Club: March 2016
Ümit Görkem1, Cihan ToğruL1, Emine Arslan1, Nafiye Yılmaz2,
Ziya Kalem,MD Gurgan Clinic IVF and Women Health Center
UOG Journal Club: May 2017 Increased nuchal translucency thickness and risk of neurodevelopmental disorders S.G. Hellmuth, L.H. Pedersen, C.B. Miltoft,
UOG Journal Club: May 2017 Increased nuchal translucency thickness and risk of neurodevelopmental disorders S.G. Hellmuth, L.H. Pedersen, C.B. Miltoft,
Overview of Prenatal Care
Aneuploidy and NTD screening
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
عنوان طرح : تعیین محدوده نرمال طول استخوان های بلند جنینی در سه ماهه دوم در مراجعین به درمانگاه های منتخب دانشگاه علوم پزشکی شیراز Normal ranges of fetal.
UOG Journal Club: April 2017
غربالگری ناهنجاریهای جنین
Down Syndrome : screening evolution and natural history
Prenatal Screening for Genetic Conditions
guidance on antenatal screening
Lower Hudson Valley Community Health Dashboard: Maternal and Infant Health in Westchester, Rockland, and Orange counties Last Updated: 3/20/2019.
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
Additive effect of factors related to assisted conception on the reduction of maternal serum pregnancy-associated plasma protein A concentrations and.
UOG Journal Club: February 2012
IN THE NAME OF GOD First trimester screening for aneuploidy
Percentage of all inborn infants ≥34 weeks’ gestation who (A) received ampicillin or (B) had CRP measured during the first 3 days surrounding the practice.
WHAT IS AVAILABLE WHEN? Non-invasive prenatal testing
UOG Journal Club: September 2019
Presentation transcript:

Epidemiological Monitoring and Quality Control of Nuchal Translucency Jack Canick Intensive Course on Screening for Down’s Syndrome Wolfson Institute of Preventive Medicine London May 2013 BROWN Women & Infants ’

NT Training Programs Fetal Medicine Foundation Less formalized systems

Overview  Epidemiological monitoring is the study of the measurements made on the population being tested  Application of serum marker experience to nuchal translucency monitoring  Examples of monitoring activities for nuchal translucency  New sonographer data

The Level of Maternal Serum AFP Increases with Increasing Gestation Palomaki GE, unpublished data log-linear increase slope = +15% per week

Nuchal Translucency Thickness Increases with Increasing Gestation Schuchter et al, Prenat Diagn 1998; 18: log-linear increase slope = +20% per week

MS AFP (MoM) NT (MoM) NT AFP SD of log MoM = 0.15 SD of log MoM = 0.10 The Distribution of AFP and NT MoM in Unaffected Pregnancies

Why is NT such a good marker? NT (MoM) hCG (MoM) unaffected DS NT: 0.11 SD 50% DR 1% FPR hCG: 0.24 SD 50% DR 8% FPR

NT parameters that are monitored: Rate of increase with CRLlog-linear over 10,3 - 13,6 weeks should go up by ~ 20% per week Mediancalculated MoM values should be stable at 1.0 MoM SD of the distributioncalculated SD of the log MoM values expected to be about 0.1 Nuchal Translucency (NT) Epidemiological monitoring

NT medians by CRL: All Centers NT change with gestation

NT medians by CRL: All Centers median MoM Distribution width

Epidemiologic Monitoring of Nuchal Translucency: Monthly Medians - A

Epidemiologic Monitoring of Nuchal Translucency: Monthly Medians - B

NT data monitoring  Use objective criteria as guide  Partially subjective process  Look for trends  Sample volume must be considered  What to do with very small volume sonographers?  Sonographer feedback has been minimally useful

Getting started: Newly trained sonographers  Provide paired CRL and NT measurements to the laboratory  If more than one sonographer within a center, identify each person within the database  Expect data to conform to parameters defined in literature

New sonographer A NT (mm) CRL (mm) Reference (slope +20% per week) New sonographer A +14%

Sonographer variation: New sonographer B Reference (slope +20% per week) New sonographer B +48%

Reference (slope +20% per week) New sonographer C CRL (mm) NT (mm) 1 3 Sonographer challenges: New sonographer C ? Reference (slope +20% per week) New sonographer B

Schielen PC et al., Prenat Diagn 2006;26:711-8 Published Literature: Variation in NT median measurement FMF-certified centers Non-FMF certified

Crossley JA et al. BJOG 2002;109: Inter-operator variation at one hospital Range of NT measurements (in MoM) between hospitals Published Literature: Variation in NT median measurement

NT Epidemiologic Monitoring Impact of Using A Single Population Median risk: 1 in 230 Center A is routinely high: result 1.3mm median 0.8mm Center B is routinely average: result 0.8mm median 0.8mm Center C is routinely low: result 0.6mm median 0.8mm == 1.67 MoM == 0.75 MoM == 1.00 MoM Example of a 30 year old who has the most typical result at 12 wks risk: 1 in 2400 risk: 1 in 3500 Patient-specific risk varies 15 fold.

14 NT Epidemiologic Monitoring Impact of Using Center-Specific Medians Patient-specific risk is the same at each center. Center A is routinely high: result 1.3mm median 1.3mm Center B is routinely average: result 0.8mm median 0.8mm Center C is routinely low: result 0.6mm median 0.6mm == 1.00 MoM = = Example of a 30 year old who has the most typical result at 12 wks risk: 1 in 2400

Palomaki GE et al. Genet Med 2008;10(2):